Skip to main content
. 2015 Dec 4;30(2):270–286. doi: 10.1038/eye.2015.217

Figure 2.

Figure 2

Mean change from baseline in visual acuity and number of injections in real-world studies and pivotal randomised controlled studies after 12 months of ranibizumab treatment in patients with wet AMD. *Represents average data for the 20 studies included in the current review (see Table 3).